{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:31:52Z","timestamp":1794900712985,"version":"4.9.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>CD19 chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed\/refractory diffuse large B-cell lymphoma (R\/R-DLBCL), but challenges such as posttreatment failure and immune-related adverse events (AEs) persist. This study explores the gut microbiome as a predictive biomarker for CAR T-cell therapy outcomes and toxicity. Stool and serum samples from patients with R\/R-DLBCL were analyzed at apheresis (47 samples) and 1 month after infusion (32 samples) using whole-genome sequencing metagenomics. When compared with healthy controls and newly-diagnosed DLBCL, R\/R-DLBCL showed significant gut dysbiosis, characterized by increased Proteobacteria and Enterobacteriaceae. Responders had higher levels of Bacteroides fragilis, whereas nonresponders exhibited higher levels of Faecalibacterium prausnitzii. Functional metagenomic analysis suggested enrichment of inosine biosynthesis pathways in responders, and elevated serum inosine demonstrated an exploratory association with improved progression-free survival. Distinct microbial taxa and serum fatty acid profiles were also linked to CAR T-cell\u2013related AEs, with higher acetate and butyrate levels in patients without AEs and increased isovalerate in those with AEs. These findings indicate that gut microbiome features\u2014particularly Bacteroides fragilis and inosine metabolism\u2014may serve as candidate biomarkers for CAR T-cell therapy outcomes and toxicity. However, given the exploratory nature of these analyses and the limited cohort size, results should be interpreted cautiously. Larger, prospective studies will be required to validate these observations and to assess the potential of microbiome-based strategies to optimize CAR T-cell therapy in R\/R-DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016858","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T21:01:30Z","timestamp":1765314090000},"page":"1634-1645","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-5297","authenticated-orcid":false,"given":"Sang Eun","family":"Yoon","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woorim","family":"Kang","sequence":"additional","affiliation":[{"name":"2CJ Bioscience Inc, Seoul, Korea"},{"name":"3Department of Biological Science, Kangwon National University, Chuncheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhun","family":"Cho","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8606-0283","authenticated-orcid":false,"given":"Hyeon Ji","family":"Cho","sequence":"additional","affiliation":[{"name":"5Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Chalita","sequence":"additional","affiliation":[{"name":"2CJ Bioscience Inc, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8560-7132","authenticated-orcid":false,"given":"Hyun-Seok","family":"Oh","sequence":"additional","affiliation":[{"name":"2CJ Bioscience Inc, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Hyun","sequence":"additional","affiliation":[{"name":"2CJ Bioscience Inc, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9444-6240","authenticated-orcid":false,"given":"Sujeong","family":"Han","sequence":"additional","affiliation":[{"name":"6Department of Artificial Intelligence, Chung-Ang University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"2CJ Bioscience Inc, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0500-3131","authenticated-orcid":false,"given":"Hojun","family":"Sung","sequence":"additional","affiliation":[{"name":"7Department of Biology and Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"7Department of Biology and Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bon","family":"Park","sequence":"additional","affiliation":[{"name":"5Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ju","family":"Ryu","sequence":"additional","affiliation":[{"name":"5Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6861-3282","authenticated-orcid":false,"given":"Duck","family":"Cho","sequence":"additional","affiliation":[{"name":"5Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea"},{"name":"8Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4401","authenticated-orcid":false,"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"},{"name":"5Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"4","key":"2026030915463008800_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2026030915463008800_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5045\/br.2023.2023177","article-title":"Recent advances in cellular immunotherapy for lymphoid malignancies","volume":"58","author":"Chung","year":"2023","journal-title":"Blood Res"},{"issue":"1","key":"2026030915463008800_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12672-025-01860-5","article-title":"Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia","volume":"16","author":"Tan","year":"2025","journal-title":"Discov Oncol"},{"issue":"3","key":"2026030915463008800_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2026030915463008800_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"S1","key":"2026030915463008800_bib6","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.5045\/br.2023.2023015","article-title":"Practical issues in CAR T-cell therapy","volume":"58","author":"Byun","year":"2023","journal-title":"Blood Res"},{"issue":"3","key":"2026030915463008800_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3343\/alm.2023.0388","article-title":"Current challenges in chimeric antigen receptor T-cell therapy in patients with B-cell lymphoid malignancies","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Med"},{"issue":"5","key":"2026030915463008800_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","article-title":"A multicenter real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in large B-cell lymphomas","volume":"5","author":"Stella","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026030915463008800_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2026030915463008800_bib10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"2026030915463008800_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","article-title":"PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells","volume":"30","author":"Lee","year":"2022","journal-title":"Mol Ther"},{"issue":"18","key":"2026030915463008800_bib12","first-page":"2224","article-title":"The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma","volume":"141","author":"Yoon","year":"2023","journal-title":"Blood"},{"issue":"27","key":"2026030915463008800_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026030915463008800_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"S2","key":"2026030915463008800_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hon.3163_45","article-title":"Phase 2 study of anbal-cel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma-Interim analysis result","volume":"41","author":"Kim","year":"2023","journal-title":"Hematological Oncol"},{"issue":"1","key":"2026030915463008800_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-065X.2011.01075.x","article-title":"The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA","volume":"245","author":"Surana","year":"2012","journal-title":"Immunol Rev"},{"issue":"4","key":"2026030915463008800_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/19490976.2015.1056973","article-title":"A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function","volume":"6","author":"Telesford","year":"2015","journal-title":"Gut Microbes"},{"issue":"1","key":"2026030915463008800_bib18","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/s41467-019-09884-6","article-title":"Bacteroides fragilis polysaccharide A induces IL-10 secreting B and T cells that prevent viral encephalitis","volume":"10","author":"Ramakrishna","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"2026030915463008800_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41422-020-00417-1","article-title":"Inosine: novel microbiota-derived immunostimulatory metabolite","volume":"30","author":"Kroemer","year":"2020","journal-title":"Cell Res"},{"issue":"6510","key":"2026030915463008800_bib20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"issue":"2","key":"2026030915463008800_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"issue":"7","key":"2026030915463008800_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s42255-020-0219-4","article-title":"Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction","volume":"2","author":"Wang","year":"2020","journal-title":"Nat Metab"},{"issue":"44","key":"2026030915463008800_bib23","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/s41388-020-01480-z","article-title":"Multifaceted role of branched-chain amino acid metabolism in cancer","volume":"39","author":"Peng","year":"2020","journal-title":"Oncogene"},{"key":"2026030915463008800_bib24","doi-asserted-by":"crossref","first-page":"736739","DOI":"10.3389\/fvets.2021.736739","article-title":"Biological function of short-chain fatty acids and its regulation on intestinal health of poultry","volume":"8","author":"Liu","year":"2021","journal-title":"Front Vet Sci"},{"issue":"1","key":"2026030915463008800_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/biom15010085","article-title":"Butyrate supplementation improves intestinal health and growth performance in livestock: a review","volume":"15","author":"Chen","year":"2025","journal-title":"Biomolecules"},{"issue":"6","key":"2026030915463008800_bib26","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1073\/pnas.1322269111","article-title":"The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition","volume":"111","author":"Chang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"43","key":"2026030915463008800_bib27","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026030915463008800_bib28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2024025366","article-title":"Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy","volume":"145","author":"Prasad","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1634\/2506265\/blooda_adv-2025-016858-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1634\/2506265\/blooda_adv-2025-016858-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:46:42Z","timestamp":1773085602000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1634\/557203\/Microbiome-and-metabolite-biomarkers-of-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016858","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,27]]}}}